



#2CE/12
01-29-03

VIA HAND DELIVERY JANUARY 21ST, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Yu et al.

Attorney Docket No.: PF141P4

Application Serial No.: 09/246,129

Art Unit: 1647

Filed: February 8, 1999

Examiner: Romeo, D.

Title: TUMOR NECROSIS FACTOR-GAMMA

RECEIVED

JAN 23 2003

TECH CENTER 1600/2900

AMENDMENT WITH RESPONSE UNDER 37 C.F.R. § 1.111 TO PAPER NO. 25

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action mailed October 21, 2002 please consider the following amendments and remarks. Submitted concurrently herewith are: (a) a Fee Transmittal Sheet; (b) a Statement By Attorney For Applicants Regarding Permanence And Availability Of Deposited Plasmids; (c) a Version With Markings Showing Changes Made; and (d) a Request for Examiner Interview.

Please amend the specification as follows:

In the Specification

Please replace the paragraph spanning lines 21-36 on page 39 with the following rewritten paragraph:

--The remaining TNF-gamma-alpha expression constructs were used to express various TNF-gamma muteins from bacterial, baculoviral, and mammalian systems. Four N-terminal deletion mutations have been generated using the pQE60 bacterial expression vector. These N-terminal deletion mutation constructs are: (i) pQE60TNFg-3/147

E¹